The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global RNAi for Therapeutic Market Research Report 2025
Synopsis
RNA interference (RNAi) is a biological process in which RNA molecules inhibit gene expression, typically by causing the destruction of specific mRNA molecules. Historically, it was known by other names, including co-suppression, post-transcriptional gene silencing (PTGS), and quelling. Only after these apparently unrelated processes were fully understood did it become clear that they all described the RNAi phenomenon. RNAi is now known as precise, efficient, stable and better than antisense technology for gene suppression.
The global RNAi for Therapeutic market was valued at US$ 176 million in 2023 and is anticipated to reach US$ 2218 million by 2030, witnessing a CAGR of 43.1% during the forecast period 2024-2030.
Global RNAi for Therapeutic key players include Alnylam Pharmaceuticals, Arbutus Biopharma (Tekmira), Arrowhead, Dicerna Pharmaceuticals, Mirna Therapeutics, etc. Global top five manufacturers hold a share over 85%.
US is the largest market, with a share over 75%, followed by EU, which has a share about 3%.
In terms of product, siRNA is the largest segment, with a share over 55%. And in terms of application, the largest application is Cancer, followed by HBV, Cardiovascular, etc.
This report aims to provide a comprehensive presentation of the global market for RNAi for Therapeutic, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding RNAi for Therapeutic.
Report Scope
The RNAi for Therapeutic market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global RNAi for Therapeutic market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the RNAi for Therapeutic companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Alnylam Pharmaceuticals
Arbutus Biopharma (Tekmira)
Arrowhead
Dicerna Pharmaceuticals
Mirna Therapeutics
Quark Pharmaceuticals
RXi Pharmaceuticals
Silence Therapeutics
Benitec Biopharma
miRagen Therapeutics
Sylentis
Gradalis
Sirnaomics
Silenseed
Segment by Type
siRNA
miRNA
shRNA
Segment by Application
Cancer
Cardiovascular
HBV
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of RNAi for Therapeutic companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
RNA interference (RNAi) is a biological process in which RNA molecules inhibit gene expression, typically by causing the destruction of specific mRNA molecules. Historically, it was known by other names, including co-suppression, post-transcriptional gene silencing (PTGS), and quelling. Only after these apparently unrelated processes were fully understood did it become clear that they all described the RNAi phenomenon. RNAi is now known as precise, efficient, stable and better than antisense technology for gene suppression.
The global RNAi for Therapeutic market was valued at US$ 176 million in 2023 and is anticipated to reach US$ 2218 million by 2030, witnessing a CAGR of 43.1% during the forecast period 2024-2030.
Global RNAi for Therapeutic key players include Alnylam Pharmaceuticals, Arbutus Biopharma (Tekmira), Arrowhead, Dicerna Pharmaceuticals, Mirna Therapeutics, etc. Global top five manufacturers hold a share over 85%.
US is the largest market, with a share over 75%, followed by EU, which has a share about 3%.
In terms of product, siRNA is the largest segment, with a share over 55%. And in terms of application, the largest application is Cancer, followed by HBV, Cardiovascular, etc.
This report aims to provide a comprehensive presentation of the global market for RNAi for Therapeutic, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding RNAi for Therapeutic.
Report Scope
The RNAi for Therapeutic market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global RNAi for Therapeutic market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the RNAi for Therapeutic companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Alnylam Pharmaceuticals
Arbutus Biopharma (Tekmira)
Arrowhead
Dicerna Pharmaceuticals
Mirna Therapeutics
Quark Pharmaceuticals
RXi Pharmaceuticals
Silence Therapeutics
Benitec Biopharma
miRagen Therapeutics
Sylentis
Gradalis
Sirnaomics
Silenseed
Segment by Type
siRNA
miRNA
shRNA
Segment by Application
Cancer
Cardiovascular
HBV
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of RNAi for Therapeutic companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global RNAi for Therapeutic Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 siRNA
1.2.3 miRNA
1.2.4 shRNA
1.3 Market by Application
1.3.1 Global RNAi for Therapeutic Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Cancer
1.3.3 Cardiovascular
1.3.4 HBV
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global RNAi for Therapeutic Market Perspective (2019-2030)
2.2 RNAi for Therapeutic Growth Trends by Region
2.2.1 Global RNAi for Therapeutic Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 RNAi for Therapeutic Historic Market Size by Region (2019-2024)
2.2.3 RNAi for Therapeutic Forecasted Market Size by Region (2025-2030)
2.3 RNAi for Therapeutic Market Dynamics
2.3.1 RNAi for Therapeutic Industry Trends
2.3.2 RNAi for Therapeutic Market Drivers
2.3.3 RNAi for Therapeutic Market Challenges
2.3.4 RNAi for Therapeutic Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top RNAi for Therapeutic Players by Revenue
3.1.1 Global Top RNAi for Therapeutic Players by Revenue (2019-2024)
3.1.2 Global RNAi for Therapeutic Revenue Market Share by Players (2019-2024)
3.2 Global RNAi for Therapeutic Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by RNAi for Therapeutic Revenue
3.4 Global RNAi for Therapeutic Market Concentration Ratio
3.4.1 Global RNAi for Therapeutic Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by RNAi for Therapeutic Revenue in 2023
3.5 RNAi for Therapeutic Key Players Head office and Area Served
3.6 Key Players RNAi for Therapeutic Product Solution and Service
3.7 Date of Enter into RNAi for Therapeutic Market
3.8 Mergers & Acquisitions, Expansion Plans
4 RNAi for Therapeutic Breakdown Data by Type
4.1 Global RNAi for Therapeutic Historic Market Size by Type (2019-2024)
4.2 Global RNAi for Therapeutic Forecasted Market Size by Type (2025-2030)
5 RNAi for Therapeutic Breakdown Data by Application
5.1 Global RNAi for Therapeutic Historic Market Size by Application (2019-2024)
5.2 Global RNAi for Therapeutic Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America RNAi for Therapeutic Market Size (2019-2030)
6.2 North America RNAi for Therapeutic Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America RNAi for Therapeutic Market Size by Country (2019-2024)
6.4 North America RNAi for Therapeutic Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe RNAi for Therapeutic Market Size (2019-2030)
7.2 Europe RNAi for Therapeutic Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe RNAi for Therapeutic Market Size by Country (2019-2024)
7.4 Europe RNAi for Therapeutic Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific RNAi for Therapeutic Market Size (2019-2030)
8.2 Asia-Pacific RNAi for Therapeutic Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific RNAi for Therapeutic Market Size by Region (2019-2024)
8.4 Asia-Pacific RNAi for Therapeutic Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America RNAi for Therapeutic Market Size (2019-2030)
9.2 Latin America RNAi for Therapeutic Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America RNAi for Therapeutic Market Size by Country (2019-2024)
9.4 Latin America RNAi for Therapeutic Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa RNAi for Therapeutic Market Size (2019-2030)
10.2 Middle East & Africa RNAi for Therapeutic Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa RNAi for Therapeutic Market Size by Country (2019-2024)
10.4 Middle East & Africa RNAi for Therapeutic Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Alnylam Pharmaceuticals
11.1.1 Alnylam Pharmaceuticals Company Detail
11.1.2 Alnylam Pharmaceuticals Business Overview
11.1.3 Alnylam Pharmaceuticals RNAi for Therapeutic Introduction
11.1.4 Alnylam Pharmaceuticals Revenue in RNAi for Therapeutic Business (2019-2024)
11.1.5 Alnylam Pharmaceuticals Recent Development
11.2 Arbutus Biopharma (Tekmira)
11.2.1 Arbutus Biopharma (Tekmira) Company Detail
11.2.2 Arbutus Biopharma (Tekmira) Business Overview
11.2.3 Arbutus Biopharma (Tekmira) RNAi for Therapeutic Introduction
11.2.4 Arbutus Biopharma (Tekmira) Revenue in RNAi for Therapeutic Business (2019-2024)
11.2.5 Arbutus Biopharma (Tekmira) Recent Development
11.3 Arrowhead
11.3.1 Arrowhead Company Detail
11.3.2 Arrowhead Business Overview
11.3.3 Arrowhead RNAi for Therapeutic Introduction
11.3.4 Arrowhead Revenue in RNAi for Therapeutic Business (2019-2024)
11.3.5 Arrowhead Recent Development
11.4 Dicerna Pharmaceuticals
11.4.1 Dicerna Pharmaceuticals Company Detail
11.4.2 Dicerna Pharmaceuticals Business Overview
11.4.3 Dicerna Pharmaceuticals RNAi for Therapeutic Introduction
11.4.4 Dicerna Pharmaceuticals Revenue in RNAi for Therapeutic Business (2019-2024)
11.4.5 Dicerna Pharmaceuticals Recent Development
11.5 Mirna Therapeutics
11.5.1 Mirna Therapeutics Company Detail
11.5.2 Mirna Therapeutics Business Overview
11.5.3 Mirna Therapeutics RNAi for Therapeutic Introduction
11.5.4 Mirna Therapeutics Revenue in RNAi for Therapeutic Business (2019-2024)
11.5.5 Mirna Therapeutics Recent Development
11.6 Quark Pharmaceuticals
11.6.1 Quark Pharmaceuticals Company Detail
11.6.2 Quark Pharmaceuticals Business Overview
11.6.3 Quark Pharmaceuticals RNAi for Therapeutic Introduction
11.6.4 Quark Pharmaceuticals Revenue in RNAi for Therapeutic Business (2019-2024)
11.6.5 Quark Pharmaceuticals Recent Development
11.7 RXi Pharmaceuticals
11.7.1 RXi Pharmaceuticals Company Detail
11.7.2 RXi Pharmaceuticals Business Overview
11.7.3 RXi Pharmaceuticals RNAi for Therapeutic Introduction
11.7.4 RXi Pharmaceuticals Revenue in RNAi for Therapeutic Business (2019-2024)
11.7.5 RXi Pharmaceuticals Recent Development
11.8 Silence Therapeutics
11.8.1 Silence Therapeutics Company Detail
11.8.2 Silence Therapeutics Business Overview
11.8.3 Silence Therapeutics RNAi for Therapeutic Introduction
11.8.4 Silence Therapeutics Revenue in RNAi for Therapeutic Business (2019-2024)
11.8.5 Silence Therapeutics Recent Development
11.9 Benitec Biopharma
11.9.1 Benitec Biopharma Company Detail
11.9.2 Benitec Biopharma Business Overview
11.9.3 Benitec Biopharma RNAi for Therapeutic Introduction
11.9.4 Benitec Biopharma Revenue in RNAi for Therapeutic Business (2019-2024)
11.9.5 Benitec Biopharma Recent Development
11.10 miRagen Therapeutics
11.10.1 miRagen Therapeutics Company Detail
11.10.2 miRagen Therapeutics Business Overview
11.10.3 miRagen Therapeutics RNAi for Therapeutic Introduction
11.10.4 miRagen Therapeutics Revenue in RNAi for Therapeutic Business (2019-2024)
11.10.5 miRagen Therapeutics Recent Development
11.11 Sylentis
11.11.1 Sylentis Company Detail
11.11.2 Sylentis Business Overview
11.11.3 Sylentis RNAi for Therapeutic Introduction
11.11.4 Sylentis Revenue in RNAi for Therapeutic Business (2019-2024)
11.11.5 Sylentis Recent Development
11.12 Gradalis
11.12.1 Gradalis Company Detail
11.12.2 Gradalis Business Overview
11.12.3 Gradalis RNAi for Therapeutic Introduction
11.12.4 Gradalis Revenue in RNAi for Therapeutic Business (2019-2024)
11.12.5 Gradalis Recent Development
11.13 Sirnaomics
11.13.1 Sirnaomics Company Detail
11.13.2 Sirnaomics Business Overview
11.13.3 Sirnaomics RNAi for Therapeutic Introduction
11.13.4 Sirnaomics Revenue in RNAi for Therapeutic Business (2019-2024)
11.13.5 Sirnaomics Recent Development
11.14 Silenseed
11.14.1 Silenseed Company Detail
11.14.2 Silenseed Business Overview
11.14.3 Silenseed RNAi for Therapeutic Introduction
11.14.4 Silenseed Revenue in RNAi for Therapeutic Business (2019-2024)
11.14.5 Silenseed Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
